<DOC>
	<DOCNO>NCT00203723</DOCNO>
	<brief_summary>The purpose study determine combination risperidone ECT improve patient 's response depression compare ECT alone .</brief_summary>
	<brief_title>Use Risperidone ECT Treatment Resistant Depression</brief_title>
	<detailed_description>Medication resistance antidepressant therapy , Treatment-Resistant Depression ( TRD ) , main reason , main indication , patient presently refer electroconvulsive therapy ( ECT ) hop rapid , definitive response ( APA 2001 ECT Task Force Report ) . While cause TRD remain unclear , category patient include incomplete remission , relapse rapidly frequently , psychotic depression , develop chronic depression , often comorbid medical psychiatric illness ( Sackeim 2001 , Sharma 2001 , Fava Davidson 1996 , Thase 1995 ) . Moreover , increase age per se barrier antidepressant response , many elderly , especially comorbid medical neurological illness , unable tolerate course aggressive pharmacotherapy seem less robust response pharmacotherapy , possibly ECT alone , significant residual functional cognitive impairment ( Reynolds 1998 , Stoudemire 1998 , Lebowitz 1997 , Gurland 1991 ) . Compared patient medication resistant , generally retain high likelihood response ECT alone , patient TRD low response rate ECT average estimate response ECT alone 50-60 % ( APA 2001 ECT Task Force ) . Additionally , ECT patient may provide acute remission , patient TRD remain high risk rapid relapse ( Sackeim 2001 , Petrides 2001 , Sackeim 1990 , Aronson 1987 ) . Consequently , ECT alone may insufficient achieve remission prevent relapse . Interestingly , resistance type medication find also predict resistance ECT alone , i.e. , resistance tricyclic antidepressant correlate less likely response ECT , though prediction hold serotonin reuptake inhibitor ( Prudic 1996 , Prudic 1990 ) . In general , patient TRD , study support use combine medication approach , specifically , demonstrate safety , tolerability effectiveness antidepressant antipsychotic medication , though usually patient comorbid psychosis ( Wheeler 2000 , Shelton 1999 , Barak 1999 ) . Case report exist ECT literature safety tolerability ECT antipsychotic , improve efficacy , albeit generally patient psychotic depression treatment resistant psychosis ( Kupchik 2000 , Bhatia 1998 , Ranjan 1996 , Farah , Beale , Kellner 1995 , Minter 1979 ) . However , study systematically , prospectively , investigate whether specific combination ECT plus atypical antipsychotic offer true treatment alternative improve efficacy ECT patient TRD . This study review experience outcome combine ECT atypical antipsychotic medication , risperidone , TRD various population academic , university-based setting , furthermore , explore pilot randomize open-label study whether ECT plus risperidone bear closer scrutiny rigorous study design novel treatment approach .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Age 18 89 year , inclusive Male female Inpatient outpatient ECT current diagnosis unipolar bipolar depression , without psychosis , accord DSMIV criterion . HAMD ( 17item ) score &gt; 17 MADRS score &gt; 18 screen first treatment session . MMSE &lt; 23 Inability consent ECT Current diagnosis schizophrenia schizoaffective disorder Current diagnosis Parkinson â€™ Disease Dementia , include Lewy Body Disease History allergic reaction risperidone History Neuroleptic Malignant Syndrome Current pregnancy positive urine pregnancy test Women breastfeed Active alcohol illicit substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>mood disorder</keyword>
	<keyword>affective disorder</keyword>
	<keyword>depression</keyword>
	<keyword>treatment-resistant</keyword>
</DOC>